High Concentrations of Sodium Chloride Improve Microbicidal Activity of Ibuprofen against Common Cystic Fibrosis Pathogens

Pharmaceuticals
Adrián J MuñozDante M Beltramo

Abstract

Ibuprofen (IBU-H), a widely used anti-inflammatory, also shows a marked antimicrobial effect against several bacterial species, including those involved in cystic fibrosis such as Pseudomona aeruginosa, methicillin resistant Staphylococcus aureus and Burkholderia cepacia complex. Additionally, our results show significant synergy between water soluble Na-ibuprofen (IBU-Na) and ionic strength. Salt concentrations above 0.5 M modify the zeta potential promoting the action of Na-IBU; thus, with 1 M sodium chloride, IBU-Na is ten times more efficient than in the absence of ionic strength, and the minimum effective contact time is reduced from hours to minutes. In short time periods, where neither IBU-Na nor controls with 1 M NaCl show activity, the combination of both leads to a reduction in the bacterial load. We also analyzed whether the changes caused by salt on the bacterial membrane also promoted the activity of other microbicide compounds used in cystic fibrosis like gentamicin, tobramycin and phosphomycin. The results show that the presence of ionic strength only enhanced the bactericidal activity of the amphipathic molecule of IBU-Na. In this respect, the effect of saline concentration was also reflected in the surface prop...Continue Reading

Associated Clinical Trials

May 11, 2020·Néstor H García

References

Mar 30, 1995·The New England Journal of Medicine·M W KonstanP B Davis
Feb 1, 1995·Letters in Applied Microbiology·K T Elvers, S J Wright
May 1, 1996·American Journal of Respiratory and Critical Care Medicine·M RobinsonP T Bye
Jun 1, 1997·Trends in Microbiology·J Davies, G D Wright
Sep 13, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D C Hooper
Jan 28, 2003·American Journal of Physiology. Lung Cellular and Molecular Physiology·Harriet CorvolAnnick Clement
Jun 17, 2003·The Journal of Pharmacology and Experimental Therapeutics·Michael W KonstanCharles L Hoppel
Dec 10, 2003·Current Opinion in Biotechnology·Christine T Barrett, John F Barrett
Nov 4, 2004·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·D M Livermore
Jan 28, 2005·Antimicrobial Agents and Chemotherapy·Keith Poole
Jan 20, 2006·The New England Journal of Medicine·Scott H DonaldsonRichard C Boucher
Aug 23, 2006·Archives of Disease in Childhood·S Rao, J Grigg
Dec 27, 2007·The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Médicale·Jm Conly, Bl Johnston
Sep 25, 2008·Current Opinion in Pulmonary Medicine·Michael W Konstan
Feb 24, 2009·Annual Review of Biochemistry·Hiroshi Nikaido
Apr 17, 2009·The Cochrane Database of Systematic Reviews·Peter Wark, Vanessa M McDonald
May 14, 2014·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Stewart T Cole
Feb 25, 2015·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Jelena ObadBlaženka Kos
Feb 3, 2016·Scientific Reports·Flavien PilletMarie-Pierre Rols

❮ Previous
Next ❯

Methods Mentioned

BETA
chemical modification

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.